Balyasny Asset Management
RCUS icon

Balyasny Asset Management’s Arcus Biosciences RCUS Stock Holding History

Balyasny Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-815,561
Closed -$19.4M – 3419
2025
Q4 		$19.4M Buy
815,561
+715,188
+713% +$14.6M 0.02% 734
2025
Q3 		$1.37M Sell
100,373
-62,439
-38% -$649K ﹤0.01% 1991
2025
Q2 		$1.33M Buy
+162,812
New +$1.39M ﹤0.01% 1932
2025
Q1 		– Sell
-58,194
Closed -$867K – 3203
2024
Q4 		$867K Buy
58,194
+9,614
+20% +$157K ﹤0.01% 1995
2024
Q3 		$743K Buy
+48,580
New +$766K ﹤0.01% 2082
2024
Q1 		– Sell
-515,453
Closed -$9.85M – 3034
2023
Q4 		$9.85M Buy
515,453
+51,003
+11% +$815K 0.02% 867
2023
Q3 		$8.34M Sell
464,450
-1,402,266
-75% -$28.2M 0.02% 914
2023
Q2 		$37.9M Buy
+1,866,716
New +$35.5M 0.08% 324
2023
Q1 		– Sell
-22,025
Closed -$455K – 3066
2022
Q4 		$455K Buy
+22,025
New +$606K ﹤0.01% 1883
2022
Q3 		– Sell
-408,122
Closed -$10.3M – 3197
2022
Q2 		$10.3M Buy
+408,122
New +$9.99M 0.03% 637
2022
Q1 		– Sell
-149,730
Closed -$6.06M – 2775
2021
Q4 		$6.06M Buy
149,730
+84,857
+131% +$3.29M 0.02% 791
2021
Q3 		$2.26M Sell
64,873
-1,774
-3% -$55.2K 0.01% 1085
2021
Q2 		$1.83M Sell
66,647
-217,879
-77% -$6.22M 0.01% 1054
2021
Q1 		$7.99M Buy
284,526
+231,205
+434% +$8.05M 0.04% 553
2020
Q4 		$1.38M Buy
+53,321
New +$1.29M 0.01% 945
2020
Q2 		– Sell
-151,677
Closed -$2.1M – 1429
2020
Q1 		$2.1M Buy
+151,677
New +$1.89M 0.03% 609

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Balyasny Asset Management's RCUS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 815,561 shares — an estimated $19.4M sold.

Balyasny Asset Management first reported a position in RCUS in Q1 2020 and held it in 16 quarters. The position peaked at $37.9M in Q2 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Balyasny Asset Management reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 815,561 Arcus Biosciences shares in Q1 2026, an estimated $19.4M.
  • Balyasny Asset Management first reported a position in Arcus Biosciences in Q1 2020 and held it in 16 quarters.
  • Balyasny Asset Management's Arcus Biosciences position peaked at $37.9M in Q2 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.